# EDGAR Filing Document

**Accession Number:** 0001421642
**File Stem:** 0001104659-26-012339
**Filing Date:** 2026-2
**Character Count:** 5100
**Document Hash:** ece24d2207c89ba02111ac137b7b3db0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-012339.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001104659-26-012339

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260210

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Satellos Bioscience Inc.
- **CENTRAL INDEX KEY:** 0001421642
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43107
- **FILM NUMBER:** 26613452

**BUSINESS ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1
- **BUSINESS PHONE:** 416-708-0522

**MAIL ADDRESS:**
- **STREET 1:** ROYAL BANK PLAZA, S. TOWER, 200 BAY ST.
- **STREET 2:** SUITE 2800
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5J 2J1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ICO THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071218

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**(Commission File No. 001-43107)**

**SATELLOS BIOSCIENCE INC.**

**(Translation of registrant's name into English)**

**Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800**

**Toronto, Ontario, ON M5J 2J3**

**(Address of registrant's principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ◻ Form 40-F ⌧

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ◻

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](tm264479d10_ex99-1.htm) | [News Release dated February 10, 2026. Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026](tm264479d10_ex99-1.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Satellos Bioscience Inc.**

---

| | |
|:---|:---|
| By: | /s/ Elizabeth Williams, CPA, CA |
| Name: | Elizabeth Williams, CPA, CA |
| Title: | Chief Financial Officer |

---

Date: February 10, 2026

## Exhibit 99.1

**Exhibit 99.1**

![](tm264479d10_ex99-1img001.jpg)

**Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026** 

TORONTO, Feb. 10, 2026 (BUSINESS WIRE) — <u>Satellos Bioscience Inc.</u> (Nasdaq: **MSLE**, TSX: **MSCL**) ("Satellos" or the "Company"), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET.

The fireside chat will be available via <u>live webcast</u> on the <u>Events and Presentations page</u> in the Investors section of the Company's website. A replay will be available following the event.

Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting may contact their Guggenheim representative or reach out directly to Satellos at <u>ir@satellos.com</u>.

**ABOUT SATELLOS BIOSCIENCE INC.**

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit <u>www.satellos.com</u>.

**CONTACTS**

Investors: Liz Williams, CFO, <u>ir@satellos.com</u><br> Media: Emily Williams, Senior Director of Communications, <u>media@satellos.com</u>